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ABSTRACT
Recent studies have demonstrated an important role for circulating serotonin in regulating bone mass in rodents. In addition, patients
treated with selective serotonin reuptake inhibitors (SSRIs) have reduced areal bone mineral density (aBMD). However, the potential
physiologic role of serotonin in regulating bone mass in humans remains unclear. Thus we measured serum serotonin levels in a
population-based sample of 275 women and related these tototal-body and spine aBMD assessed by dual-energy X-ray absorptiometry,
femur neck totaland trabecular volumetric BMD (vBMD)and vertebraltrabecular vBMD assessed by quantitative computed tomography
(QCT), and bone microstructural parameters at the distal radius assessed by high-resolution peripheral QCT (HRpQCT). Serotonin levels
wereinverselyassociatedwithbodyandspineaBMD(age-adjustedR¼ 0.17and 0.16, P<.01,respectively)andwithfemurnecktotal
and trabecular vBMD (age-adjusted R¼ 0.17 and  0.25, P<.01 and<.001, respectively) but not lumbar spine vBMD. Bone volume/
tissue volume, trabecular number, and trabecular thickness at the radius were inversely associated with serotonin levels (age-adjusted
R¼ 0.16,  0.16, and  0.14, P<.05, respectively). Serotonin levels also were inversely associated with body mass index (BMI; age-
adjusted R¼ 0.23, P<.001). Multivariable models showed that serotonin levels remained significant negative predictors of femur neck
total and trabecular vBMD, as well as trabecular thickness at the radius, after adjusting for age and BMI. Collectively, our data provide
support for a physiologic role for circulating serotonin in regulating bone mass in humans.  2010 American Society for Bone and
Mineral Research.
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Introduction
R
ecent elegant genetic studies in rodents have demonstrated
a key role for circulating serotonin (5-hydroxytryptamine,
5-HT) in regulating bone formation and skeletal mass.
(1) These
studies have shown that low-density lipoprotein (LDL)-receptor-
related protein 5 (LRP5), which is assumed to be a coreceptor for
WNT proteins,
(2) may regulate bone formation and bone mass
not through direct effects on osteoblasts but rather indirectly by
suppressing serotonin production in the duodenum via
inhibition of the expression of tryptophan hydroxylase 1 (Tph1),
the rate-limiting enzyme for serotonin synthesis.
(1) Serotonin
appears to act on osteoblasts through the 5-hydroxytryptamine
receptor1b(Htr1b)andinhibitstheirproliferation.Consistentwith
this, circulating serotonin levels that were decreased by means of
a low-tryptophan diet normalized bone formation and bone mass
in LRP5-deficient mice, and gut- but not osteoblast-specific LRP5
inactivation decreased bone formation in a b-catenin-indepen-
dent manner. Conversely, gut-specific activation of LRP5 or
inactivation of Tph1 increased bone mass and prevented
ovariectomy-induced bone loss.
(1)
These findings in rodents are consistent with the limited data
in humans that suggest an important role for serotonin in
regulating bone metabolism. Thus Yadav and colleagues
(1)
extended their findings in rodents to humans with LRP5 loss-of-
function mutations, which cause the osteoporosis pseudoglioma
(OPPG) syndrome characterized by severely reduced bone mass,
and showed that serum serotonin levels were elevated at
approximately 250ng/mL in the sera of the three OPPG patients
analyzed as compared with control subjects, who had a mean
serum serotonin level of approximately 50ng/mL. Conversely,
platelet-poor plasma serotonin levels were suppressed in two
subjects with high bone mass owing to activating mutations in
LRP5.
(1)
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415Further support for an important role for serotonin in bone
metabolismcomesfromstudiesinpatientstreatedwithselective
serotonin reuptakeinhibitors (SSRIs),whichincrease extracellular
serotonin levels. Thus, in data from the Study of Osteoporotic
Fractures (SOF), use of SSRIs, but not tricyclic antidepressants,
was associated with increased rates of bone loss at the hip.
(3)
Similarly, use of SSRIs, but not other antidepressants, was
associated with reduced BMD at multiple skeletal sites in men.
(4)
Finally, recent data indicate that daily SSRI use was associated
with a twofold increase in the risk of clinical fragility fractures
after adjustment for potential covariates.
(5) Consistent with these
findings, both deletion
(6,7) and inhibition
(7) of the serotonin (5-
HT) transporter in rodents is associated with reduced bone mass.
Despite these findings in rodents and in patients treated with
SSRIs, there are currently no data in subjects not being treated
with these agents regarding a possible physiologic role for
circulating serotonin levels in regulating bone turnover or mass
in humans. Thus we measured serum serotonin levels in a
population-based cohort of women and related these to
anthropometric measures, bone turnover markers, and bone
density/structural parameters at multiple skeletal sites using a
combination of dual-energy X-ray absorptiometry (DXA),
quantitative computed tomography (QCT), and high-resolution
peripheral QCT (HRpQCT).
Methods
Study subjects
We recruited 375 women from an age-stratified random sample
of Rochester, Minnesota residents, who were selected using the
medicalrecordslinkageoftheRochesterEpidemiologyProject.
(8)
This population ishighly characteristic of the whitepopulation of
the United States, but blacks, Asians, and Hispanics are
underrepresented. The sample spanned ages from 21 to 97
years. For the present analysis, we excluded 99 women on
medications that potentially could affect circulating serotonin
levels (i.e., SSRIs, adrenergic blockers, adrenergic stimulants,
alpha blockers, alpha-adrenergic agonists, anticholinergic
agents, anticonvulsants, antidepressants, antipsychotics, beta
blockers, and gastrointestinal prokinetic agents) or on corticos-
teroids, bisphosphonates, and selective estrogen receptor
modulators. One woman with a very high serotonin level
[402ng/mL, >4 standard deviations (SDs) above the mean] also
was excluded. The analysis thus was based on 275 women: 90 of
these were premenopausal, 125 were postmenopausal and were
not taking hormone therapy (HT, defined as oral or transdermal
estrogen preparations with or without a progestin), and 60 were
postmenopausal and taking some form of HT. We defined
menopause as the absence of menses for greater than 6 months.
Reflecting the ethnic composition of the community, 98.5% of
the women were white. All studies were approved by the Mayo
Institutional Review Board, and written informed consent was
obtained from all subjects prior to evaluation.
Study protocol
Subjects were admitted to the outpatient Clinical Research Unit
following an overnight fast. They consumed their habitual diet
the day prior to study without any dietary restrictions. Height (m)
and weight (kg) were measured using a customized height
gauge (Mayo Section of Engineering) and an electronic weight
scale (Model 5002, Scale-Tronix, Inc., White Plains, NY, USA), and
body mass index (BMI) was defined as killiograms per square
meter (kg/m
2). Following a blood draw, the subjects underwent
the various imaging procedures described below.
Sample collection
The samples for this study were collected from December 2000
through March 2004. Venous blood was withdrawn into
uncoated clot tubes (BD Biosciences, San Jose, CA, USA). After
agglutination, the blood was centrifuged at room temperature
for 10 minutes at 1000 g. The serum was divided into 0.5mL
aliquotsand immediately frozenat  808Cuntil used fordifferent
assays. The samples were thawed immediately before use, and
only previously unthawed aliquots were used for the serotonin
assay. A previous study from our group
(9) has demonstrated the
stabilityof osteocalcin,arelatively unstable protein,
(10) underour
collection and storage conditions.
Serum measurements
Serum serotonin levels were measured using a competitive
enzyme-linked immunosorbent assay (ELISA; Immuno-Biological
Laboratories, Inc., Minneapolis, MN, USA; interassay coefficient of
variation 6%). Serum calcium and phosphorus levels were
measured by autoanalyzer (Roche Diagnostic Corp., Indianapolis,
IN, USA; interassay coefficient of variation 5%). Serum 25-
hydroxyvitamin D [25(OH)D] was measured by a competitive
protein-binding assay (Nichols Institute Diagnostics, Capistrano,
CA, USA; interassay coefficient of variation <15%), and serum
parathyroid hormone (PTH) was measured using a two-site
immunoassay for intact PTH (Diagnostic Products Corporation,
Los Angeles, CA, USA; interassay coefficient of variation <13%).
Serum osteocalcin was measured using a two-site immunor-
adiometric assay (CIS-US, Bedford, MA, USA; interassay coeffi-
cientofvariation8%).Serumamino-terminalpropeptideoftypeI
collagen (PINP) was measured by radioimmunoassay (DiaSorin,
Stillwater, MN, USA; interassay coefficient of variation <9%).
Serum cross-linked C-telopeptide of type I collagen (CTx) was
measured using an ELISA (Nordic Biosciences, Herlev, Denmark;
interassay coefficient of variation <10%).
Total-body DXA
This study was designed originally to focus on volumetric QCT
parametersanddidnotincludesite-specificDXAmeasuresofthe
spine or hip. However, the subjects did have a total-body DXA
performed (Prodigy, GE Medical Systems, Madison, WI, USA)
using software version 6.10.029. From this, we derived the total-
body areal bone mineral density (aBMD), fat mass (kg), and lean
mass (kg). In addition, we were able to obtain the spine region
aBMD from the total-body scans. We have previously shown that
such scans are equivalent to dedicated lumbar spine DXA
measurements in women, with R¼0.92 and an error in
predicting lumbar spine BMD of 6.5%.
(11)
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As described previously,
(12,13) single-energy CT scans were made
at the lumbar spine and proximal femur with a multidetector
Light Speed QX-I scanner (GE Medical Systems, Wakesha, WI,
USA). Calibration standards scanned with the patient were used
to convert CT numbers directly to equivalent volumetric BMD
(vBMD) in milligrams per cubic centimeter (mg/cm
3).
(14) To study
age- and sex-specific structural changes in bone mineral
distribution and structure, we developed software for the
analysis of bone structure, geometry and volumetric density
from the CT images, specific details of which have been
described previously.
(13) To validate our image-processing
algorithm, we made 10 scans of the European Spine Phantom,
which is composed of hydroxyapatite.
(15) The correlation
between bone density results determined by our algorithm
and that of the spine phantom was r¼0.998; using scans of L2
from the phantom over 10 days, vBMD was estimated to have a
coefficient of variation (CV) of 0.7%.
HRpQCT
Details regarding the HRpQCT imaging used in this cohort have
been reported previously
(16) and are summarized briefly here.
Owing to the lack of availability of this new instrument initially,
the HRpQCT measurements were done approximately 2 years
after the other measurements and in 243 (83%) of the 275
women used in these analyses (80 premenopausal women, 109
postmenopausal women not on HT, and 54 postmenopausal
women on HT). The nondominant wrist (or in the case of a prior
wrist fracture, the nonfractured wrist) was scanned using an
HRpQCT device (a prototype of the XtremeCT, Scanco Medical
AG, Bassersdorf, Switzerland). The in vivo measurement protocol
included the acquisition of a 3D stack of 116 high-resolution QCT
slices at the distal end of the radius using an effective energy of
40keV, slice thickness of 89mm, field of view of 90mm, image
matrix of 1024 1024 pixels, and pixel size of 89mm.
The processing and analysis of the images also have been
described extensively and validated.
(17–20) Briefly, bone volume/
total volume (BV/TV) is first derived from the trabecular vBMD.
Recognizing that individual trabeculae will not be resolved at
their correct thickness owing to partial-volume effects, a
thickness-independent structure extraction was employed to
assess trabecular microarchitecture. To this end, the 3D ridges
(the center points of the trabeculae) were detected in the gray-
level images as described in detail in Laib and colleagues.
(18)
Trabecular number (TbN, 1/mm) then was taken as the inverse of
the mean spacing of the ridges.
(19) Combining TbN and BV/TV,
trabecular thickness (TbTh, mm) then was derived as BV/TV  
TbN, and trabecular separation (TbSp, mm) was derived as (1 –
BV/TV)   TbN, as is done in standard histomorphometry.
(21) The
validity of this approach has been rigorously tested by
comparing the HRpQCT methodology with 28-mm-resolution
micro-CT
(20) withvery high correlation (correlation coefficients of
0.96–0.99) between the micro-CT and HRpQCT measurements.
The key point in this analysis is that the resolution has to be
sufficient to adequately resolve the distance between the
trabecular ridges (1/TbN, or 300 to500mm) and not necessarily
to resolve individual trabeculae ( 100mm or less).
Statistical analysis
Data are summarized as means and SDs. The two-sample t test
was used for comparisons between groups in Table 1.
Unadjusted and age-adjusted Pearson correlation coefficients
were used to assess the relationship between serum serotonin
levels and the various anthropometric, serum, and skeletal
parameters in Table 2. Multivariable models were constructed
using age, BMI, and serotonin levels to assess the relative
importance of these variables in predicting skeletal
parameters. A P value of less than .05 was considered significant.
Results
Table 1 shows the anthropometric, serum, and bone density/
structural parameters in all the study subjects as well as
separately in the premenopausal women, postmenopausal
women not on HT, and postmenopausal women on HT.
Postmenopausal women not on HT, but not those on HT, had
a higher BMI than the premenopausal women. This was due to
an increase in fat mass, as determined by total-body DXA. Serum
serotonin levels were significantly lower in postmenopausal
women not on HT than in premenopausal women; postmeno-
pausal women on HT had intermediate levels not different from
either of the two other groups. Serum calcium and phosphorus
levels were slightly higher in the postmenopausal women not on
HT, and serum 25(OH)D was slightly lower in both groups of
postmenopausal women than in premenopausal women,
whereas serum PTH levels were significantly higher in both
groups of postmenopausal women. Bone formation markers
(osteocalcinandPINP)tendedtobehigher,andserumCTXlevels
were significantly higher in the postmenopausal women not on
HT than in the premenopausal women. Osteocalcin, PINP, and
CTX levels were significantly lower in postmenopausal women
on HT than in either premenopausal women or postmenopausal
women not on HT.
Total-body and spine aBMD values by DXA were significantly
lower in both groups of postmenopausal women than in
premenopausal women. Similar reductions in the central QCT
measures at the femur neck and vertebrae, as well as the distal
radius HRpQCT parameters (BV/TV, TbN, and TbTh), were present
in the postmenopausal as compared with the premenopausal
women, with an increase TbSp in the postmenopausal groups.
Table 2 shows the unadjusted and age-adjusted correlation
coefficients between serum serotonin and the anthropometric,
serum, and bone density/structural parameters. Serum serotonin
levels were significantly inversely associated with BMI in all
women (Fig. 1), with the strongest negative association noted in
the postmenopausal women not on HT. This inverse association
seemed to be most closely related to fat mass because the
correlationsbetweenserotoninlevelsandfatmasswerestronger
than those between serotonin and lean mass. Since postmeno-
pausalwomennotonHThadsignificantlylowerserumserotonin
levelsthan premenopausalwomenbutalsohadhigherBMIs(see
Table 1), we further tested whether serum serotonin levels were
different in the pre- versus postmenopausal women not on HT
following adjustment for BMI. In this analysis, differences in BMI
were found to account for the differences in serotonin levels
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BMI¼.167).
There were positive associations between serum serotonin
and calcium and phosphorus levels in the premenopausal
womenbutnotinthe other groups(see Table 2).Boneformation
and resorption markers tended to be positively associated with
serotonin levels, reachingstatistical significance forage-adjusted
correlations with PINP and unadjusted and age-adjusted
correlations with serum CTX levels in premenopausal women.
As also shown in Table 2, there were significant inverse
associations between serum serotonin levels and total-body
aBMDfollowingadjustmentforageinallwomen.Thiswasdriven
principally by inverse unadjusted and age-adjusted correlations
between serotonin levels and total-body aBMD in the
postmenopausal women not on HT. The pattern for DXA spine
aBMD was similar, except that at this site the correlations also
were statistically significant in premenopausal women following
adjustment for age.
Femur neck total vBMD also was inversely associated with
serum serotonin levels in all women and in postmenopausal
women not on HT following adjustment for age (see Table 2). A
similar pattern was seen for femur neck trabecular vBMD, with
Table 1. Anthropometric, Serum, and Bone Density/Structural Parameters in the Study Subjects
Postmenopausal
All women Premenopausal Not on HRT On HRT
N 275 90 125 60
Age (years) 57.9 17.7 38.3 9.0 69.3 12.2
    63.7 10.6
   ,yy
Anthropometric parameters
Height (m) 162.2 6.5 164.4 5.7 161.4 6.7
   160.8 6.2
   
Weight (kg) 73.2 16.3 71.6 16.5 75.9 16.3 70.1 15.3
y
BMI (kg/m
2) 27.8 5.7 26.4 5.7 29.0 5.3
   27.2 6.1
y
Lean mass (kg) 35.8 4.8 37.5 4.4 35.2 5.1
   34.4 4.0
   
Fat mass (kg) 33.6 12.5 30.6 13.9 36.7 10.8
    31.7 12.6
yy
Serum parameters
Serotonin (ng/mL) 84.9 52.3 95.0 54.5 78.7 52.6
  82.6 46.6
Calcium (mg/dL) 9.4 0.4 9.3 0.3 9.6 0.4
    9.4 0.3
yy
Phosphorus (mg/dL) 3.5 0.4 3.5 0.5 3.6 0.4
  3.5 0.3
25(OH)D (ng/mL) 22.3 10.1 26.1 12.9 20.2 7.9
    20.8 8.1
  
PTH (pmol/L) 3.6 1.6 3.0 1.2 4.0 1.7
    3.7 1.7
  
Osteocalcin (ng/mL) 19.7 8.7 19.8 7.8 21.3 9.5 16.2 7.1
  ,yyy
PINP (mg/L) 37.8 17.6 38.7 16.5 41.4 19.3 29.1 12.0
   ,yyy
CTX (ng/mL) 0.49 0.26 0.48 0.26 0.56 0.26
  0.38 0.21
  ,yyy
DXA BMD parameters
Total-body BMD (g/cm
2) 1.14 0.11 1.19 0.09 1.11 0.12
    1.13 0.10
   
Spine BMD (g/cm
2) 1.11 0.16 1.16 0.15 1.08 0.16
    1.09 0.15
  
Central QCT parameters
Femur neck
Total vBMD (mg/cm
3) 334 74 391 58 296 59
    325 67
   ,yy
Trabecular vBMD (mg/cm
3) 214 59 259 46 184 49
    207 51
   ,yy
Cortical vBMD (mg/cm
3) 581 83 633 70 548 75
    567 77
   
Vertebrae
Trabecular vBMD (mg/cm
3) 154 44 190 27 130 39
    152 36
   ,yyy
HRpQCT parameters
a
BV/TV 0.126 0.033 0.136 0.027 0.119 0.035
   0.124 0.033
 
TbN (1/mm) 2.50 0.26 2.56 0.19 2.49 0.31 2.46 0.23
  
TbTh (mm) 0.050 0.010 0.053 0.008 0.047 0.011
    0.050 0.010
TbSp (mm) 0.354 0.054 0.340 0.035 0.362 0.066
   0.360 0.047
  
Data aremean SD. BMI¼body mass index;25(OH)D¼25-hydroxyvitamin D; PTH¼parathyroidhormone; PINP¼amino-terminal propeptideof type I
collagen; CTX¼cross-linked C-telopeptide of type I collagen; DXA¼dual-energy X-ray absorptiometry; BMD¼bone mineral density; vBMD¼volumetric
BMD; BV/TV¼bone volume/total volume; TbN¼trabecular number; TbTh¼trabecular thickness; TbSp¼trabecular separation.
aAs noted in the ‘‘Methods,’’ the HRpQCT data were available in a subset of the women.
 P<.05,
  P<.01,
   P<.001 versus premenopausal women;
yP<.05,
yyP<.01,
yyyP<.001 versus postmenopausal women not on HT.
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justed and age-adjusted) present in premenopausal women. No
associations were found between femur neck cortical vBMD and
serotonin levels in any of the groups. Vertebral trabecular vBMD
was inversely associated with serum serotonin levels in
postmenopausal women not on HT following adjustment for
age, but not in the other groups.
BV/TV, TbN, and TbTh were inversely and TbSp was positively
associated with serum serotonin levels following adjustment for
age in all women. As for the DXA and central QCT parameters,
these associations were driven principally by the correlations
between these microstructural parameters and serotonin levels
in postmenopausal women not on HT (see Table 2).
While the data in Table 2 are shown following age adjustment,
inadditionalanalyses,wealsoperformedfurtheradjustmentsfor
creatinine clearance, serum 25(OH)D, and PTH levels in these
subjects. The results remained identical to those shown in
Table 2, except that the correlations of serotonin with lean mass
in all women and with spine BMD in premenopausal women
were no longer significant (data not shown).
Since the inverse associations between serotonin and BMI
could represent an additional confounder, we constructed
multivariable models with bone density and structural para-
meters as the dependent variables and allowed age, BMI, and
serum serotonin levels to compete in these models. Table 3
showstheresultsofthesemodelsforspecificskeletalparameters
and groups of women where serotonin levels remained as
significant predictors. Thus, for femur neck total and trabecular
vBMD in all women and trabecular vBMD in premenopausal
women, serum serotonin levels remained as significant negative
predictors even after age and BMI had entered the models. Since
femur neck trabecular vBMD in premenopausal women was
significantly inversely associated with serotonin both in the
unadjusted (see Table 2) and multivariable models (see Table 3),
Figure 2 shows the plot of this relationship. Serum serotonin also
remained as a significant negative predictor in models of TbTh in
allwomen,aswellasTbThandBV/TVinpostmenopausal women
not on HT (see Table 3).
Discussion
In this study, we demonstrate significant inverse associations
between serum serotonin levels and a number of measures of
bone density/structure assessed using a combination of DXA,
central QCT, and HRpQCT. For femur neck total and trabecular
vBMD and TbTh in all women, for femur neck trabecular vBMD in
premenopausal women, and for BV/TV and TbTh at the radius in
postmenopausal women not on HT, these associations remained
significant in multivariable models that included age and BMI,
consistent with an independent effect of circulating serotonin
levels on bone mass/structure at these sites. While the
associations wefound wererelatively weak, they wereconsistent
in terms of the direction of the associations in the different
groups of women and were statistically significant. Thus our data
do support recent findings in rodent models
(1,6,7) implicating a
physiologic role for serotonin in regulating bone mass. We
should note, however, that since we did not correct for possible
multiple comparisons, further studies in additional cohorts are
needed to validate our findings.
Circulating serotonin is derived principally from the enter-
ochromaffin cells found in gastrointestinal tract crypts and is
rapidly taken up by platelets.
(22) The serotonin stored in platelets
is released during the collection of serum; thus serum serotonin
levels are approximately 100-fold higher than platelet-poor
plasma levels.
(23) It is at present unclear whether serum or
platelet-poor plasma serotonin levels are the best ‘‘index’’ of gut
serotonin production. In addition, there are different methods
available to determine serotonin levels, such as high-pressure
liquid chromatography (HPLC)/fluorometry, HPLC/electrochemi-
cal, or liquid chromatography-mass spectrometry (LC/MS)
techniques. The HPLC assays are considered the gold standard;
however, Yadav and colleagues,
(1) using the same serotonin
assay as used in this study, found that the three OPPG patients
tested had approximately fivefold higher serum serotonin levels
than the mean of their control subjects; in the same study, two
patients with high bone mass owing to activating LRP5
mutations had an approximately 50% reduction in platelet-poor
plasma serotonin levels. Previous studies have found increased
serum and platelet-poor plasma serotonin levels in patients with
active rheumatoid arthritis compared with control subjects,
(23)
and immunoassays for serotonin have been used previously in a
number of studies in humans.
(24,25) Since we only had serum and
not platelet-poor plasma in our study subjects, we could not
compare serum versus platelet-poor plasma serotonin levels for
associations with the bone density/structural parameters. In
addition, serum (or platelet-poor plasma) serotonin levels are
altered by diet, particularly tryptophan intake,
(1) and while all our
samples were collected fasting at about 8 a.m., we did not
control for dietary factors that might have altered circulating
serotoninlevels.Thusitispossiblethattheassociationswenoted
may have been stronger had we used platelet-poor plasma
instead of serum for our measurements and been able to control
the diet of the study subjects prior to the blood draw.
The study by Yadav and colleagues
(1) demonstrated that gut-
derived serotonin principally regulated bone formation in vivo
and osteoblast proliferation in vitro, with no clear effect on bone
Fig. 1. Relation of BMI to serum serotonin levels in all women.
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earlier studies demonstrating that serotonin can enhance
osteoclast differentiation in vitro.
(26) Interestingly, in our human
study we found positive associations between serum serotonin
and PINP levels (following age adjustment) as well as between
serumserotoninandCTXlevels(unadjustedandage-adjusted)in
premenopausal women. These findings suggest that, in humans,
increased circulating serotonin levels may be associated with
increased bone turnover. Thus the effects of serotonin on bone
metabolisminhumansmaybemorecomplexthansuggestedby
the study by Yadav and colleagues,
(1) and direct interventional
studies (e.g., using serotonin infusions) are likely needed to
better define the effects of serotonin in regulating bone
formation and resorption in humans.
We did find that serum serotonin levels were inversely
associated with BMI and that this association was driven
principally by fat mass. The inverse relation between serotonin
and body mass has been described previously,
(27–31) and it has
been suggested that serotonin plays an important role in the
regulation of appetite and food satiety, resulting in reduced
caloric intake. Furthermore, serotonergic drugs, such as
fluoxetine (an SSRI), have been shown to result in significantly
greater weight loss than placebo treatment.
(32–35) In contrast,
blocking serotonin synthesis resulted not only in a prevention of
serotonin-induced hypophagia but also an increase in food
intake.
(36)
We also found that serum serotonin levels were lower in
postmenopausal women not on HT than in premenopausal
Table 2. Unadjusted/Age-Adjusted Correlation Coefficients Between Serum Serotonin Levels and Anthropometric, Serum, and Bone
Density/Structural Parameters in the Study Subjects
All women Premenopausal
Postmenopausal
Not on HT On HT
Age (years)  0.12
 /– 0.08/–  0.04/–  0.13/–
Anthropometric parameters
Height (m) 0.02/ 0.02 0.07/0.06  0.05/ 0.08  0.03/ 0.06
Weight (kg)  0.21
   / 0.21
     0.09/ 0.10  0.30
   / 0.33
     0.14/ 0.18
BMI (kg/m
2)  0.23
   / 0.23
     0.14/ 0.15  0.32
   / 0.34
     0.13/ 0.16
Lean mass (kg)  0.09/ 0.13
  0.03/0.03  0.21
 / 0.24
    0.16/ 0.20
Fat mass (kg)  0.19
  / 0.18
    0.09/ 0.10  0.27
  / 0.30
     0.11/ 0.15
Serum parameters
Calcium (mg/dL) 0.05/0.08 0.31
  /0.33
    0.00/0.00 0.09/0.08
Phosphorus (mg/dL) 0.08/0.10 0.22
 /0.23
  0.09/0.10  0.15/ 0.15
25(OH)D (ng/mL) 0.13
 /0.10 0.10/0.12 0.08/0.07 0.18/0.18
PTH (pmol/L)  0.13
 / 0.10  0.08/ 0.09  0.02/ 0.02  0.32
 / 0.31
 
Osteocalcin (ng/mL) 0.11/0.10 0.09/0.15 0.16/0.15 0.06/0.02
PINP (mg/L) 0.07/0.05 0.16/0.21
  0.05/0.04  0.04/ 0.08
CTX (ng/mL) 0.04/0.03 0.23
 /0.29
    0.03/ 0.03  0.10/ 0.12
DXA BMD parameters
Total-body BMD (g/cm
2)  0.10/ 0.17
    0.09/ 0.09  0.23
  / 0.29
    0.01/ 0.06
Spine BMD (g/cm
2)  0.12
 / 0.16
    0.20/ 0.21
   0.22
 / 0.24
   0.06/0.05
Central QCT parameters
Femur neck
Total vBMD (mg/cm
3)  0.03/ 0.17
    0.16/ 0.15  0.17/ 0.24
    0.04/ 0.09
Trabecular vBMD (mg/cm
3)  0.07/ 0.25
     0.25
 / 0.26
   0.17/ 0.28
    0.13/ 0.20
Cortical vBMD (mg/cm
3) 0.06/ 0.01  0.01/ 0.01  0.06/ 0.08 0.09/0.06
Vertebrae
Trabecular vBMD (mg/cm
3) 0.00/ 0.12  0.15/ 0.13  0.16/ 0.22
  0.11/0.07
HRpQCT parameters
BV/TV  0.11/ 0.16
   0.10/ 0.11  0.29
  / 0.29
   0.06/0.04
TbN (1/mm)  0.12/ 0.16
   0.06/ 0.06  0.26
  / 0.28
   0.03/0.01
TbTh (mm)  0.11/ 0.14
   0.12/ 0.12  0.26
  / 0.26
   0.04/0.03
TbSp (mm) 0.12/0.18
   0.08/0.08 0.28
  /0.30
    0.04/ 0.03
Significant (P<.05) correlations are indicated in bold. BMI¼body mass index; 25(OH)D¼25-hydroxyvitamin D; PTH¼parathyroid hormone;
PINP¼amino-terminal propeptide of type I collagen; CTX¼cross-linked C-telopeptide of type I collagen; DXA¼dual-energy X-ray absorptiometry;
BMD¼bone mineral density; vBMD¼volumetric BMD; BV/TV¼bone volume/total volume; TbN¼trabecular number; TbTh¼trabecular thickness;
TbSp¼trabecular separation.
 P<.05,
  P<.01,
   P<.001.
420 Journal of Bone and Mineral Research MO ¨DDER ET AL.women. However, this does not appear to be an effect of
menopause per se because differences in serotonin levels
between pre- and postmenopausal women not on HT were no
longer significant following adjustment for differences in BMI.
We also should note that while we found significant associations
between serum serotonin levels and bone mass/structural
parameters in postmenopausal women not on HT, these
associations were not present in the postmenopausal women
on HT. This could be due to biologic effects of HT in modulating
the relationship between serotonin and bone or to the smaller
sample size of postmenopausal women on HT (n¼60) as
compared with those not onHT (n¼125),and further studies are
needed to test whether estrogen may modulate the skeletal
effects of serotonin on bone.
In summary, our study does provide support for a possible
physiologic role for circulating serotonin levels in regulating
bone density/structure in women. However, while statistically
significant, the associations we found were relatively weak. This
maybedue,atleastinpart,tothefactthatweusedserum(rather
than platelet-poor plasma) for our measurements and did not
control the dietary intake of our study subjects. In addition, our
data indicate thathigher serotonin levelsmaybe associated with
increased bone turnover rather than simply reduced bone
formation. These caveats notwithstanding, our findings should
provide an impetus for additional studies aimed at unraveling
the potential role of serotonin in regulating bone metabolism in
humans.
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